Research / Stocks / ANIK ANIK Nasdaq CIK 0000898437
Anika Therapeutics, Inc. · Surgical & Medical Instruments & Apparatus
COVERAGE / STANDARD
Latest filing 4 · Aug 5, 2026
Research state Latest filing analysis is current
Last SEC check Sep 14, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT Anika Therapeutics, Inc.'s latest supported as-filed period reports revenue of $32.6M ; gross margin moved 1425 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Capex intensity 36th Own-history percentile · N=14
Method Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.44% · OPTIONAL
Operating cash generation 29th Own-history percentile · N=14
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -2.10% · OPTIONAL
Revenue growth 100th Own-history percentile · N=10
Method Yoy · gp.fundamentals.revenue
Raw value 15.56% · CORE
Inventory pressure 57th Own-history percentile · N=14
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 87.60% · OPTIONAL
Gross margin 86th Own-history percentile · N=14
Method Level · gp.fundamentals.gross_margin
Raw value 65.15% · CORE
Operating margin 100th Own-history percentile · N=14
Method Level · gp.fundamentals.operating_margin
Raw value 9.06% · CORE
R&D intensity 71th Own-history percentile · N=14
Method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 30, 2026 General Corporate
Capital Allocation 4 evidence-backed dimensions Capex Intensity Stable Cash Generation Stable R And D Intensity Stable Sbc Intensity Improving [email protected] · 15 historical states · 50% confidenceCompany Direction 8 evidence-backed dimensions Capex Intensity Stable Cash Generation Stable Inventory Pressure Inflecting Margin Inflecting Profitability Inflecting [email protected] · 15 historical states · 48% confidenceFinancial Quality 5 evidence-backed dimensions Cash Generation Stable Inventory Pressure Inflecting Margin Inflecting Profitability Inflecting Sbc Intensity Improving [email protected] · 15 historical states · 50% confidenceGovernance Evidence 4 evidence-backed dimensions Filing Amendments None Detected Auditor Changes None Detected Sbc Intensity Observed Insider Activity Observed [email protected] · 15 historical states · 50% confidenceInterpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
R And D Intensity
ANIK 22.5
Peer median 12.0
Peer percentile 63th 68 valid peers · 77% coverage · +0.8 robust σ Inventory Pressure
ANIK 87.6
Peer median 72.0
Peer percentile 71th 79 valid peers · 90% coverage · +0.5 robust σ Capex Intensity
ANIK 4.4
Peer median 3.0
Peer percentile 68th 73 valid peers · 83% coverage · +0.5 robust σ Profitability
ANIK 9.1
Peer median -6.7
Peer percentile 75th 83 valid peers · 94% coverage · +0.4 robust σ Growth
ANIK 15.6
Peer median 8.8
Peer percentile 63th 76 valid peers · 86% coverage · +0.4 robust σ Cash Generation
ANIK -2.1
Peer median -10.1
Peer percentile 56th 81 valid peers · 92% coverage · +0.2 robust σ Open group breadth → Divergence is context, not positive or negative. INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 2
Sales 0
Distinct buyers 1
Repeat buyer YES Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0001171843-26-005012 11 governed changes · top 7 shown
01
HIGH IMPORTANCE Cash 100TH HISTORICAL PCTL · N=4
Cash & equivalents decreased 27.8% Cash & equivalents changed -27.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Why this ranks here · [email protected] $53.2M → $38.4M Comparable → current
02
HIGH IMPORTANCE Margin 100TH HISTORICAL PCTL · N=3
Gross margin moved 1425 bp higher Gross margin changed +1425 basis points from the comparable as-filed period.
Why this ranks here · [email protected] 50.90% → 65.15% Comparable → current
03
HIGH IMPORTANCE Margin 100TH HISTORICAL PCTL · N=3
Gross profit increased 47.9% Gross profit changed +47.9% from the comparable as-filed period.
Why this ranks here · [email protected] $14.4M → $21.2M Comparable → current
04
HIGH IMPORTANCE Inventory 100TH HISTORICAL PCTL · N=4
Inventory increased 68.8% As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 4.44% -8.1% ↓ Capital expenditure $1.4M +1.3% ↑ Cash & equivalents $38.4M +0.0% ↑ Free-cash-flow proxy -$2.1M +66.0% ↑ Gross margin 65.15% +0.0% ↑ Interest income $426,000 -36.1% ↓ Inventory $28.6M +25.1% ↑ Net income $3.3M +165.4% ↑
ACTIVE TRACE Revenue ANIK · as filed with the SEC · reported-date aware
Capex / revenue Q2 / 2026-06-30 4.44% -8.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q2 / 2026-06-30 $1.4M +1.3% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q2 / 2026-06-30 $38.4M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q2 / 2026-06-30 -$2.1M +66.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q2 / 2026-06-30 65.15% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest income Q2 / 2026-06-30 $426,000 -36.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q2 / 2026-06-30 $28.6M +25.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q2 / 2026-06-30 $3.3M +165.4% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q2 / 2026-06-30 -$684,000 +85.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q2 / 2026-06-30 9.06% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Research & development Q2 / 2026-06-30 $7.3M +9.4% sequential point Trace ↗ Evidence inspector
Loading lineage… × Revenue Q2 / 2026-06-30 $32.6M +10.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
4 Aug 5, 2026 Period Aug 3, 2026 0001193125-26-335269SEC ↗ 10-Q Jul 29, 2026 Period Jun 30, 2026 0001171843-26-005012SEC ↗ 8-K Jul 29, 2026 Period Jul 29, 2026 0001171843-26-004977SEC ↗ 8-K Jul 14, 2026 Period Jul 10, 2026 0001171843-26-004635SEC ↗ 4 Jun 23, 2026 Period Jun 18, 2026 0001193125-26-279545SEC ↗ 4 Jun 23, 2026 Period Jun 18, 2026 0001193125-26-279542SEC ↗ 4 Jun 23, 2026 Period Jun 18, 2026 0001193125-26-279541SEC ↗ Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗